Table 1 Baseline characteristics of patients in the ITT population
Variables | Cam+nab-TP (n = 132) | Cam+TP (n = 130) | TP (n = 129) |
|---|---|---|---|
Age (years) | |||
<65 | 74 (56.1) | 79 (60.8) | 63 (48.8) |
≥65 | 58 (43.9) | 51 (39.2) | 66 (51.2) |
Median (range) | 63 (45–75) | 63 (44–75) | 65 (44–75) |
Sex, n (%) | |||
Male | 116 (87.9) | 112 (86.2) | 104 (80.6) |
Female | 16 (12.1) | 18 (13.8) | 25 (19.4) |
ECOG PS, n (%) | |||
0 | 105 (79.5) | 106 (81.5) | 104 (80.6) |
1 | 27 (20.5) | 24 (18.5) | 25 (19.4) |
Tumor location, n (%) | |||
Upper | 10 (7.6) | 12 (9.2) | 19 (14.7) |
Middle | 69 (52.3) | 75 (57.7) | 57 (44.2) |
Lower | 53 (40.2) | 43 (33.1) | 53 (41.1) |
T stage, n (%) | |||
T1b | 3 (2.3) | 1 (0.8) | 2 (1.6) |
T2 | 15 (11.4) | 13 (10.0) | 19 (14.7) |
T3 | 114 (86.4) | 116 (89.2) | 108 (83.7) |
N stage, n (%) | |||
N0 | 20 (15.2) | 24 (18.5) | 20 (15.5) |
N1 | 71 (53.8) | 71 (54.6) | 73 (56.6) |
N2 | 38 (28.8) | 33 (25.4) | 35 (27.1) |
N3 | 3 (2.3) | 2 (1.5) | 1 (0.8) |
Clinical stage, n (%) | |||
I | 3 (2.3) | 1 (0.8) | 2 (1.6) |
II | 31 (23.5) | 34 (26.2) | 35 (27.1) |
III | 95 (72.0) | 93 (71.5) | 91 (70.5) |
IVA | 3 (2.3) | 2 (1.5) | 1 (0.8) |
PD-L1 TPS, n (%) | |||
<1% | 43 (32.6) | 59 (45.4) | 49 (38.0) |
≥1% | 78 (59.1) | 61 (46.9) | 62 (48.1) |
<10% | 99 (75.0) | 98 (75.4) | 97 (75.2) |
≥10% | 22 (16.7) | 22 (16.9) | 14 (10.9) |
Unknown | 11 (8.3) | 10 (7.7) | 18 (14.0) |
PD-L1 CPS, n (%) | |||
<1 | 14 (10.6) | 18 (13.8) | 15 (11.6) |
≥1 | 109 (82.6) | 102 (78.5) | 96 (74.4) |
<10 | 68 (51.5) | 80 (61.5) | 72 (55.8) |
≥10 | 55 (41.7) | 40 (30.8) | 39 (30.2) |
Unknown | 9 (6.8) | 10 (7.7) | 18 (14.0) |
